Effects of Device and Formulation on In Vitro Performance of Dry Powder Inhalers
Open Access
- 5 April 2012
- journal article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 14 (3), 400-409
- https://doi.org/10.1208/s12248-012-9352-7
Abstract
The study examined the sensitivity of DPI in vitro performance to formulation and device changes. Rotahaler/Rotacaps was selected as the reference DPI drug product, and Aerolizer was selected as the test device. Since the test device was recognized to have much greater efficiency of dispersion, simple modifications to both formulation and device were made in an effort to provide a closer match to the in vitro performance of the reference product. The modifications included varying the drug and lactose particle sizes and/or lactose fine particle content in the test formulations, as well as lowering the specific resistance of the test device. These modifications were intended to address variables important for drug product performance for a defined experimental design and were not intended to mimic the extensive formulation and device design strategies that are employed in an industrial setting. Formulation and device modifications resulted in a modified test product that approached the reference product in the in vitro performance.Keywords
This publication has 21 references indexed in Scilit:
- In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung DiseasesThe AAPS Journal, 2009
- Prediction of Dry Powder Inhaler Formulation Performance From Surface Energetics and Blending DynamicsDrug Development and Industrial Pharmacy, 2008
- Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet sizeJournal of Pharmaceutical Sciences, 2006
- Drug Delivery Devices: Issues in Drug DevelopmentProceedings of the American Thoracic Society, 2004
- Effect of Design on the Performance of a Dry Powder Inhaler Using Computational Fluid Dynamics. Part 1: Grid Structure and Mouthpiece LengthJournal of Pharmaceutical Sciences, 2004
- In Vitro Aerosol Performance and Dose Uniformity between the Foradile® Aerolizer® and the Oxis® Turbuhaler®Journal of Aerosol Medicine, 2001
- Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulationInternational Journal of Pharmaceutics, 1999
- Effect of Particle Morphology on Emitted Dose of Fatty Acid-Treated Disodium Cromoglycate Powder AerosolsPharmaceutical Development and Technology, 1997
- Dose emissions from marketed dry powder inhalersInternational Journal of Pharmaceutics, 1995
- The Relationship Between Powder Inhaler Resistance and Peak Inspiratory Conditions in Healthy Volunteers — Implications for In Vitro TestingJournal of Aerosol Medicine, 1993